Literature DB >> 28779556

Unlicensed and off-label uses of medicines: definitions and clarification of terminology.

Jeffrey K Aronson1, Robin E Ferner2,3.   

Abstract

The terms 'licensed', 'unlicensed', and 'off-label', often used in relation to marketing and prescribing medicinal products, may confuse UK prescribers. To market a medicinal product in the UK requires a Marketing Authorization ('product licence') for specified indications under specified conditions, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The Marketing Authorization includes the product's agreed terms of use (the 'label'), described in the Summary of Product Characteristics (SmPC). Prescribing a licensed product outside those terms is called 'off-label' prescribing. Products for which no-one holds a UK Marketing Authorization are unlicensed. Prescribers can prescribe authorized products according to the conditions described in the SmPC ('on-label') or outside those conditions ('off-label'). They can also prescribe unauthorized products, even if they are unlicensed in the UK, if they are licensed elsewhere or if they have been manufactured in the UK by a licensed manufacturer as a 'special'. The complexities of this system can be understood by considering the status of the manufacturer of the product, the company that markets it (which may or may not be the same), the product itself, and its modes of use, and by emphasizing the word 'authorized'. If a Marketing Authorization is granted to the supplier of a product, it will specify the authorized modes of use; the product will be prescribable as authorized (i.e. 'on-label') or in other modes of use, which will all be off-label. Unlicensed products with no authorized modes of use can be regarded as 'unauthorized products'. All 'specials' can be regarded as authorized products lacking authorized modes of use.
© 2017 The British Pharmacological Society.

Keywords:  authorized medicines; licensed medicines; market authorization; off-label prescribing; unlicensed prescribing

Mesh:

Substances:

Year:  2017        PMID: 28779556      PMCID: PMC5698582          DOI: 10.1111/bcp.13394

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  The Rose Case reconsidered: physicians, apothecaries, and the law in Augustan England.

Authors:  H J Cook
Journal:  J Hist Med Allied Sci       Date:  1990-10       Impact factor: 2.088

2.  Shattuck lecture. Innovation, regulation, and the FDA.

Authors:  Margaret A Hamburg
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

3.  GMC is criticised for refusing to disclose reasons behind its advice to support prescribing for Lucentis rather than Avastin for wet AMD.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2015-04-13

Review 4.  Unlicensed and off-label uses of medicines: definitions and clarification of terminology.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2017-09-26       Impact factor: 4.335

5.  The state control of medicines: the first 3000 years.

Authors:  R G Penn
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

6.  Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies.

Authors:  Simon Kaja; Jill D Hilgenberg; Eric Everett; Scott E Olitsky; Jim Gossage; Peter Koulen
Journal:  Hum Antibodies       Date:  2011
  6 in total
  18 in total

Review 1.  Unlicensed and off-label uses of medicines: definitions and clarification of terminology.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2017-09-26       Impact factor: 4.335

2.  Off-label use of bevacizumab for wet age-related macular degeneration in Europe.

Authors:  Tomas Bro; Magdalena Derebecka; Øystein Kalsnes Jørstad; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-30       Impact factor: 3.117

Review 3.  Medical Devices: Definition, Classification, and Regulatory Implications.

Authors:  Jeffrey K Aronson; Carl Heneghan; Robin E Ferner
Journal:  Drug Saf       Date:  2020-02       Impact factor: 5.606

4.  Off-Label Drug Use in Pediatric Out-Patient Care: A Multi-Center Observational Study.

Authors:  Aeshah AlAzmi; Zahra Alasmari; Consuela Yousef; Ahmed Alenazi; Mohammed AlOtaibi; Hani AlSaedi; Adnan AlShaikh; Amani AlObathani; Omaima Ahmed; Loie Goronfolah; Mousa Alahmari
Journal:  Hosp Pharm       Date:  2020-08-31

Review 5.  Off-label use of drugs in pediatrics: a scoping review.

Authors:  Min Meng; Meng Lv; Ling Wang; Bo Yang; Panpan Jiao; Wenjuan Lei; Hui Lan; Quan Shen; Xufei Luo; Qi Zhou; Xuan Yu; Yangqin Xun; Ruobing Lei; Tianchun Hou; Yaolong Chen; Qiu Li
Journal:  Eur J Pediatr       Date:  2022-07-13       Impact factor: 3.860

6.  Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.

Authors:  Gudrun Hefner; Jan Wolff; Sermin Toto; Pamela Reißner; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2022-09-07       Impact factor: 3.850

7.  Recommendations on Off-Label Drug Use in Pediatric Guidelines.

Authors:  Min Meng; Qi Zhou; Wenjuan Lei; Min Tian; Ping Wang; Yunlan Liu; Yajia Sun; Yaolong Chen; Qiu Li
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

8.  Antipsychotic prescribing practices and patient, family member and healthcare professional perceptions of antipsychotic prescribing in acute care settings: a scoping review protocol.

Authors:  Natalia Jaworska; Stephana Julia Moss; Karla D Krewulak; Zara Stelfox; Daniel Niven; Zahinoor Ismail; Lisa Burry; Kirsten Fiest
Journal:  BMJ Open       Date:  2022-06-29       Impact factor: 3.006

Review 9.  Extent, reasons and consequences of off-labeled and unlicensed drug prescription in hospitalized children: a narrative review.

Authors:  Wasim Shuib; Xin-Yin Wu; Fang Xiao
Journal:  World J Pediatr       Date:  2021-06-02       Impact factor: 2.764

10.  Development of an Age-Appropriate Mini Orally Disintegrating Carvedilol Tablet with Paediatric Biopharmaceutical Considerations.

Authors:  Dilawar Khan; Daniel Kirby; Simon Bryson; Maryam Shah; Afzal Rahman Mohammed
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.